Editas Medicine (8EM) Price & Analysis

1 Followers

8EM Stock Chart & Stats

CHF2.16

CHF0.00(0.00%)

At close: Jul 29 4:00 PM EDT

CHF2.16

CHF0.00(0.00%)

Day’s Range― - ―

52-Week RangeCHF2.09 - CHF3.00

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

CHF343.42M

Enterprise ValueCHF246.12

Total Cash (Recent Filing)CHF211.65M

Total Debt (Recent Filing)CHF15.51M

Price to Earnings (P/E)―

Beta1.87

Next Earnings

Nov 09, 2026

EPS Estimate

-0.15

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.75

Shares OutstandingN/A

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)6.67

Price to Sales (P/S)4.49

P/FCF Ratio-1.10

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF4.71

Price Target Upside118.17% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering6

EPS Forecast (FY)-0.63

Revenue Forecast (FY)CHF20.76M

Bulls Say, Bears Say

Bulls Say

Improving Revenue And Gross MarginRevenue growth alongside positive gross margin indicates improving commercial and cost economics, even before product commercialization. If this trajectory continues, a stronger revenue base can support development investment and improve operating leverage as Editas advances its pipeline.

Lower Leverage And Rebuilt EquitySubstantially lower debt and rebuilt equity reduce balance-sheet pressure and improve financial flexibility relative to 2025. This gives Editas more capacity to allocate capital toward clinical programs and lowers the burden of debt service while it remains in development.

Clinical Leadership StrengtheningAdding an experienced chief medical officer strengthens clinical execution as EDIT-401 moves toward the clinic. Focused leadership can improve trial planning, regulatory coordination, and development prioritization, making the pipeline’s advancement more durable over the next several quarters.

Bears Say

Persistent Operating LossesDeep losses show that current revenue remains insufficient to fund the company’s operating and research costs. Continued unprofitability can constrain internal reinvestment, leave results dependent on pipeline progress, and keep financial performance vulnerable while programs mature.

Structurally Negative Cash FlowLarge negative operating and free cash flow means Editas is still funding research and operations well ahead of profitability. Although burn has moderated, ongoing cash consumption requires substantial reserves or new financing and remains a central constraint on execution.

Funding Reliance And DilutionThe need for equity financing reflects the gap between cash consumption and internally generated funds. While added capital supports operations, issuing shares dilutes existing holders and leaves future development dependent on continued access to external funding.

Editas Medicine News

Editas Medicine appoints Dan Ory as chief medical officer

Editas Medicine (EDIT) announced the appointment of Dan Ory as chief medical officer, effective immediately. Ory will oversee...

12d ago

EDIT

Editas Medicine files $400M mixed securities shelf

16:27 EDT Editas Medicine (EDIT) files $400M mixed securities shelf Published first on TheFly – the ultimate source...

19d ago

EDIT

Editas Medicine initiated with a Buy at Ladenburg

Ladenburg initiated coverage of Editas Medicine (EDIT) with a Buy rating and $6 price target Published first on...

1M ago

EDIT

Phil Nadeau Reiterates Buy on Editas Medicine, Citing Strong Cash Runway and Upcoming EDIT-401 Clinical Catalyst

TD Cowen analyst Phil Nadeau has maintained their bullish stance on EDIT stock, giving a Buy rating yesterday....

1M ago

EDIT

Editas Medicine Strengthens Board With New Cardiology Director

An announcement from Editas Medicine ( ($EDIT) ) is now available. On August 3, 2026, Editas Medicine director...

2M ago

EDIT

Editas Medicine reports Q2 EPS (15c), consensus (28c)

Reports Q2 revenue $11.89M, consensus $2.75M. The revenue increase was primarily attributable to the recognition of deferred revenue...

2M ago

EDIT

EDIT Earnings this Week: How Will it Perform?

Editas Medicine Inc. (EDIT) is scheduled to report 2nd quarter earnings on 08/05/2026. Regarding Q2 estimates, Wall Street...

2M ago

EDIT

Editas Medicine Shareholders Back Board, Pay and Auditor

An announcement from Editas Medicine ( ($EDIT) ) is now available. At its June 17, 2026 annual meeting,...

3M ago

EDIT

Private Markets: Bezos’ Prometheus raises $12B as OpenAI files for IPO

Jeff Bezos’ new AI venture Prometheus has raised $12B in fresh funding, pushing its valuation to about $41B....

3M ago

Editas Medicine preclinical data ‘looks highly supportive,’ says Evercore ISI

After Editas Medicine (EDIT) presented new preclinical data for EDIT-401, its lead in vivo development candidate, in an...

4M ago

EDIT

TD Cowen remains bullish on Editas Medicine after ‘compelling preclinical data’

TD Cowen notes that Editas Medicine (EDIT) presented “compelling preclinical data” at EAS detailing EDIT-401’s 90% reduction in...

4M ago

EDIT

Editas Medicine Raises Capital Through Public Equity Offering

An announcement from Editas Medicine ( ($EDIT) ) is now available. On May 26, 2026, Editas Medicine, Inc....

4M ago

EDIT

Editas Medicine 55.6M share Secondary priced at $2.25

Cantor Fitzgerald and Wells Fargo acted as joint book running managers for the offering. Published first on TheFly...

4M ago

EDIT

Editas Medicine Suspends Existing At-The-Market Offering Prospectus

Editas Medicine ( ($EDIT) ) has issued an update. On May 26, 2026, Editas Medicine, Inc. suspended and...

4M ago

EDIT

8EM FAQ

What was Editas Medicine Inc’s price range in the past 12 months?

Editas Medicine Inc lowest stock price was CHF2.09 and its highest was CHF3.00 in the past 12 months.

What is Editas Medicine Inc’s market cap?

Editas Medicine Inc’s market cap is CHF343.42M.

When is Editas Medicine Inc’s upcoming earnings report date?

Editas Medicine Inc’s upcoming earnings report date is Nov 09, 2026 which is in 50 days.

How were Editas Medicine Inc’s earnings last quarter?

Editas Medicine Inc released its earnings results on Aug 05, 2026. The company reported -CHF0.122 earnings per share for the quarter, beating the consensus estimate of -CHF0.22 by CHF0.098.

Is Editas Medicine Inc overvalued?

According to Wall Street analysts Editas Medicine Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Editas Medicine Inc pay dividends?

Editas Medicine Inc does not currently pay dividends.

What is Editas Medicine Inc’s EPS estimate?

Editas Medicine Inc’s EPS estimate is -0.15.

How many shares outstanding does Editas Medicine Inc have?

Currently, no data Available

What happened to Editas Medicine Inc’s price movement after its last earnings report?

Editas Medicine Inc reported an EPS of -CHF0.122 in its last earnings report, beating expectations of -CHF0.22. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Editas Medicine Inc?

Currently, no hedge funds are holding shares in CH:8EM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Editas Medicine Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

12.72%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Editas Medicine (8EM) Earnings & Revenues

Historic Earnings Reports

8EM Stock 12 Month Forecast

Average Price Target

CHF4.71

▲(118.17% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"CHF1","4":"CHF4","7":"CHF7","2.5":"CHF2.5","5.5":"CHF5.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6.55644192,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF6.56</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.71244263,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF4.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.27822096,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF3.28</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,2.5,4,5.5,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.156,2.4944955323076927,2.832991064615385,3.171486596923077,3.5099821292307696,3.848477661538462,4.186973193846154,4.525468726153846,4.8639642584615395,5.202459790769231,5.540955323076924,5.879450855384617,6.217946387692308,{"y":6.55644192,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.156,2.352649433076923,2.5492988661538463,2.7459482992307693,2.9425977323076924,3.1392471653846155,3.3358965984615385,3.5325460315384616,3.7291954646153846,3.9258448976923077,4.12249433076923,4.319143763846154,4.515793196923077,{"y":4.71244263,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.156,2.2423246892307693,2.3286493784615385,2.4149740676923077,2.501298756923077,2.587623446153846,2.6739481353846157,2.7602728246153845,2.846597513846154,2.932922203076923,3.0192468923076925,3.1055715815384617,3.191896270769231,{"y":3.27822096,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.919,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.919,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.919,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.919,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.919,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.919,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.919,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.919,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.919,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.919,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.919,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.156,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.156,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >